Abstract 2338P
Background
Ovarian cancer (OC) is one of the most common gynecological cancers, with the worst prognosis and the highest mortality rate. According to the FIGO, the overall five-year survival rate is approximately 50%. Tumor-associated macrophages (TAMs) are one of the most prominent populations of immune cells in both ovarian cancer tissue and malignant ascites. The most relevant task is to identify TAM subpopulations in ovarian cancer, to discover how they interact with chemotherapy and affect the development and outcome of the disease.
Methods
Patients with high-grade serous ovarian carcinoma were included in the study. FFPE samples with tumor were obtained after surgery. The study was carried out according to medical ethics. We applied two technologies of spatial transcriptomics for the analysis of TAM transcriptomic features in patients with ovarian cancer – 10x Genomics Visium and Nanostring GeoMX-DSP. All procedures were performed according to manufacturer`s protocols.
Results
The results of 10x Visium demonstrated that TAM cluster express CCL18, APOC1, GPNMB, LYZ, APOE, C1QC, C1QB, CTCB, SPP1, CTSS, and other genes. Interestingly, according to accumulating data the expression of these macrophage markers is distinctive feature for the potentially targeted population of lipid-associated TAMs. The morphology of macrophages in TAM cluster in clinical samples corresponds to the large lipid-associated TAMs. Nanostring technology allowed us to analyse ROIs with immune cells located in different tumor sites. The transcriptome of TAMs located near the tumor nest correlated to functional activation of extracellular matrix organization, antigen presentation, vascular development and myeloid leukocyte activation. These TAMs have the same morphology of large foamy macrophages and express APOE, SPP1, LYZ, CTSS, and other genes.
Conclusions
We found gene signature specific for the large TAMs in tumor tissue of patients with high-grade serous ovarian carcinoma.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Russian Science Foundation research project No 21-75-10021.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2222P - Frequent TERT gains in metastatic papillary thyroid carcinoma
Presenter: Sara Gil
Session: Poster session 16
2223P - Next-generation sequencing enables identification of RET rearrangements in papillary thyroid cancer
Presenter: Sergi Clavé
Session: Poster session 16
2224P - Identifying prognostic factors in patients with radioiodine-refractory differentiated thyroid carcinoma (RR-DTC) treated with tyrosine kinase inhibitors (TKI): Data from REGETNE registry
Presenter: Maria Victoria San Roman Gil
Session: Poster session 16
2225P - FOX1 (rs965513), NKX2-1 (rs944289) and BRAF (V600E) gene mutations and their role in development of papillary thyroid cancer
Presenter: Darko Katalinic
Session: Poster session 16
2226P - Survival benefit of radioiodine therapy (RAI) in papillary thyroid cancer variants (PTCV): A SEER analysis
Presenter: Sakhr Alshwayyat
Session: Poster session 16
2227P - The efficacy and safety of lenvatinib in neoadjuvant therapy in patients with locally advanced thyroid cancer: A single-arm phase II clinical trial
Presenter: Jianhong Yu
Session: Poster session 16
2228P - Long-term clinical outcomes of Lenvatinib in patients with differentiated thyroid cancer: Results from the real-world practice of a single institution
Presenter: Ryutaro Onaga
Session: Poster session 16
2229P - Updated safety and efficacy of selpercatinib in patients (pts) with RET-activated thyroid cancer: Data from LIBRETTO-001
Presenter: Lori Wirth
Session: Poster session 16
2323P - Multi-omic spatial phenotyping of the NSCLC tumour microenvironment for the development of a spatial score associated with immunotherapy resistance
Presenter: Arutha Kulasinghe
Session: Poster session 16
2324P - Trametinib and PD-1 combined blockade impairs tumor growth and improves survival of KRAS-mutant lung cancer through Id1 downregulation
Presenter: Ander Puyalto
Session: Poster session 16